Document is current
Any future updates will be listed below
-
Authors
Okuda, Darin T. https://orcid.org/0000-0002-6499-1523
Azevedo, Christina J.
Pelletier, Daniel
Moog, Tatum M.
Moazami, Saeed
Rezvani, Sepideh
Bovis, Francesca
Sormani, Maria Pia
Siva, Aksel
Kantarci, Orhun
Lebrun-Frénay, Christine
,
Amezcua, Lilyana
Azevedo, Christina J
Donlon, Stacy
Hua, Le H
Mowry, Ellen M
Naismith, Robert T
Okai, Annette
Okuda, Darin T
Pardo, Gabriel
Repovic, Pavle
Stüve, Olaf
Vargas, Wendy S
-
Funding
Funding for this research was provided by:
Biogen (109MS001)
- License Information
-
More Information
Article History
Received: 8 May 2024
Revised: 6 June 2024
Accepted: 10 June 2024
First Online: 9 July 2024
Declarations
:
: D.T.O. received personal compensation for consulting and advisory services from Eisai, EMD Serono, Genentech, Genzyme/Sanofi, Immunic Therapeutics, Moderna, and RVL Pharmaceuticals, Inc., Zenas BioPharma and research support from Biogen Inc., EMD Serono/Merck, and Novartis. D.T.O. has issued national and international patents along with pending patents related to the enclosed work as well as other developed technologies. D.T.O. received royalties for intellectual property licensed by The Board of Regents of The University of Texas System. D.T.O. is the Founder of Revert Health Inc. C.A. received personal compensation from EMD Serono, Genentech, Genzyme/Sanofi, Horizon Therapeutics, MJH Life Sciences, TG Therapeutics, and Zenas BioPharma. M.P.S. has been a consultant and has received research grant support from Biogen Inc. A.S. has been a consultant to Biogen Inc. O.K. has been a consultant and also received research support from Biogen Inc. for an investigator-initiated study. C.L.-F. received research support from Biogen Inc. for an investigator-initiated study. D.P., T.M.M., S.M., S.R., and F.B. report no disclosures.
